패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Race Oncology Limited 2 애널리스트 중 1 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
null null	Independent Investment Research (Aust.) Pty Ltd
Chris Kallos	MST Financial Services Pty Limited

Race Oncology 대차 대조표 상태

재무 상태 기준 확인 6/6

주요 정보

최근 재무 상태 업데이트

Is Race Oncology (ASX:RAC) In A Good Position To Deliver On Growth Plans?

We Think Race Oncology (ASX:RAC) Needs To Drive Business Growth Carefully

We're Not Very Worried About Race Oncology's (ASX:RAC) Cash Burn Rate

Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation

Companies Like Race Oncology (ASX:RAC) Are In A Position To Invest In Growth

We're Interested To See How Race Oncology (ASX:RAC) Uses Its Cash Hoard To Grow

Recent updates

Race Oncology Limited, Annual General Meeting, Nov 25, 2024

Consensus revenue estimates increase by 12%

Is Race Oncology (ASX:RAC) In A Good Position To Deliver On Growth Plans?

Price target increased by 26% to AU$3.22

New minor risk - Share price stability

New minor risk - Shareholder dilution

We Think Race Oncology (ASX:RAC) Needs To Drive Business Growth Carefully

New minor risk - Shareholder dilution

New major risk - Financial position

We're Not Very Worried About Race Oncology's (ASX:RAC) Cash Burn Rate

Race Oncology Limited Appoints Daniel Tillett as Chief Executive Officer

Race Oncology Limited, Annual General Meeting, Nov 27, 2023

Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation

New minor risk - Share price stability

New minor risk - Financial data availability

Race Oncology Limited Announces Board Changes

New minor risk - Market cap size

Race Oncology Limited Announces Board Changes

Companies Like Race Oncology (ASX:RAC) Are In A Position To Invest In Growth

Race Oncology Limited Appoints Michelle Rashford Chief Medical Officer, Effective 1 July 2023

We're Interested To See How Race Oncology (ASX:RAC) Uses Its Cash Hoard To Grow

Race Oncology Limited Appoints Damian Clarke-Bruce as Director

Race Oncology Limited Receives Human Ethics Approval for Observational Cardioprotection Breast Cancer Trial

Race Oncology Limited, Annual General Meeting, Feb 21, 2023

Board Member recently bought AU$50k worth of stock

Board Member recently bought AU$99k worth of stock

Race Oncology Limited Appoints Damian Clarke-Bruce as Managing Director, Effective 1 February 2023

Race Oncology Limited Announces It Has Submitted A Human Ethics Application to Hunter New England Human Research Ethics Committee Seeking Approval to Commence the Observational Stage of A Planned Phase 1/2B Clinical Trial of Zantrene

Race Oncology Limited Appoints Daniel (Danny) Sharp as an Independent Non-Executive Director

Race Oncology Limited Receives Positive Guidance on Zantrene Via Pre-IND Meeting with US FDA

High number of new and inexperienced directors

Race Oncology Ltd Announces Management Changes

Here's Why We're Not At All Concerned With Race Oncology's (ASX:RAC) Cash Burn Situation

Race Oncology Limited, Annual General Meeting, Nov 24, 2022

Race Oncology Limited Develops Improved Iv Formulation of Zantrene

Race Oncology Limited Initiates New Drug Discovery Program

Board Member recently bought AU$165k worth of stock

Race Oncology Limited Shares Further Interim Results from Preclinical Cardioprotection Program in Collaboration with Researchers from the University of Newcastle

Race Oncology Limited Announces Interim Results from its Preclinical Melanoma Research Program

Race Oncology Limited Expands FTO Targeting Phase 1b/2a Extramedullary AML & MDS Trial to Europe

Race Oncology Limited Announces the Dose Escalation Phase 1b Stage of the Relapsed or Refractory Acute Myeloid Leukaemia (R/R AML) Trial Running At the Chaim Sheba Medical Centre, Israel

Race Oncology Limited Appoints Guy Breitenbucher to Its Scientific Advisory Board

Race Oncology Limited Receives Governance Approval for AML EMD & MDS Trial

High number of new and inexperienced directors

Race Oncology Limited Receives Human Ethics Approval for Its Open Label Clinical Trial of Zantrene in Patients with Extramedullary Acute Myeloid Leukaemia or High-Risk Myelodysplastic Syndrome

Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation

Race Oncology Limited Announces Preclinical & Clinical Programs Update

Board Member recently bought AU$56k worth of stock

Race Oncology Limited Announces MD Anderson Cancer Center Collaborators Publish Peer Reviewed AML Preclinical Study on Zantrene

Race Oncology Limited Appoints Christina Manfre as Chief Financial Officer

Non-Independent Non-Executive Chairman recently sold AU$995k worth of stock

Board Member recently bought AU$59k worth of stock

Insider recently sold AU$4.4m worth of stock

Race Oncology Limited Announces Interim Results from the Zantrene® Preclinical Heart Safety Research Program Led by Eminent Cardiotoxicity Researchers, Associate Professors Aaron Sverdlov and Doan Ngo

Non-Independent Non-Executive Chairman exercised options to buy AU$9.8m worth of stock.

Non-Independent Non-Executive Chairman recently bought AU$710k worth of stock

Non-Executive Chairman recently sold AU$193k worth of stock

Non-Executive Chairman exercised options to buy AU$5.7m worth of stock.

Insider recently sold AU$4.3m worth of stock

Race Oncology Limited Executes Contract to Commence Phase 1b/2 AML Trial at Chaim Sheba Israel

Insider recently sold AU$4.8m worth of stock

We're Hopeful That Race Oncology (ASX:RAC) Will Use Its Cash Wisely

Insider recently sold AU$6.6m worth of stock

Race Oncology Limited Announces Compelling Preclinical Breast Cancer Results

Insider recently sold AU$2.1m worth of stock

What Percentage Of Race Oncology Limited (ASX:RAC) Shares Do Insiders Own?

New 90-day high: AU$3.29

Race Oncology Limited Announces Positive Early Preclinical Ovarian Cancer Results

Professor Borje Andersson to Resign as Chief Medical Officer of Race Oncology Limited